Private: Gallery Post #1


CADTH’s Pharmaceutical Reviews Updates are used to communicate new Common Drug Review (CDR) and pan-Canadian Oncology Drug Review (pCODR) drug review process updates to the public. PDCI has outlined below the key highlights from the most recent update. For more information, please consult the CADTH ... Read More


As PDCI announced earlier today, the PMPRB has issued the second draft of the PMPRB Guidelines to support the implementation of Patented Medicines Regulations (Regulations) changes coming unto force on January 1, 2021.  This draft is now available for a 30-day Notice and Comment Period.  Written feedback ... Read More


The Patented Medicine Prices Review Board (PMPRB) has just released its second set of Draft Guidelines under the recently amended Patented Medicines Regulations (“Regulations”).  This launches a 30-day consultation period for stakeholders to provide written comments on the new Draft Guidelines.  Stay ... Read More


As expected, amendments to the Patented Medicines Regulations (“Regulations”) were published in Canada Gazette II this morning.  The amendments officially change the coming into force date of the new amending Regulation to January 1, 2021.  These Regulations were originally published in Canada Gazette II on August 21, 2020 with an ... Read More


PMPRB Guidelines and Regulations Update As first disclosed by PDCI last week, the PMPRB Board Chair officially confirmed that the amended Patented Medicines Regulations (“Regulations”) will now come into force on January 1, 2021.  These Regulations were published in Canada Gazette II in August 2019 with ... Read More


PDCI Market Access understands from multiple sources that Health Canada is reaching out to stakeholder groups today to confirm the delay of the implementation of the PMPRB amended Regulations to January 1, 2021. Official publication of the delay in Canada Gazette to follow (likely in CG2 on June ... Read More


REMINDER: As announced last month, PDCI and its research partners are studying the private payer product listing agreement (PLA) landscape in Canada by surveying pharmaceutical manufacturers and private payers about their ... Read More


PDCI Market Access Inc. (PDCI), in collaboration with Connex Health Consulting, is excited to announce the launch of its 2020 Private Payer Product Listing Agreement (PLA) study! The objective of this research is to share insights about the private payer PLA landscape among pharmaceutical stakeholders ... Read More


PDCI Market Access Inc. (PDCI), Canada’s leading pricing, reimbursement and health economics consultancy, is pleased to announce its strategic partnership with Mark Fleming.  Mark is joining PDCI as Strategic Advisor supporting PDCI’s pricing, market access and policy research activities.   ... Read More


We are excited to announce that PDCI Market Access Inc. (“PDCI”) has entered into an Exclusive License Agreement for the rights to the Market Access Toolkit from TELUS Health Solutions Inc. The Market Access Toolkit has been a critical resource to the pharmaceutical industry for more than 20 years. First developed ... Read More